


p16


BOND-READY-TO-USE ANTIBODY

HNE

HEAD, NECK AND
ENDOCRINE PATHOLOGY



Tonsil, stained with p16 BOND Ready-to-Use Primary Antibody (6H12), PA0016



Squamous Cell Carcinoma of tonsil, stained with p16 BOND Ready-to-Use Primary Antibody (6H12), PA0016


The Novocastra p16 antibody, is the only fully automated, IVD product on market, enabling on-label assessment of p16 in Head and Neck pathology.

Code	Name	Configuration	Retrieval
PA0016	7 mL p16 BOND RTU	BOND Ready-to-Use	P(HIER)

This antibody is recommended as an adjunct to conventional histopathology using non-immunologic histochemical stains.

Deliver results you can rely on, and streamline workflow efficiency.

Novocastra antibodies, in combination with the BOND platforms, provide a fully integrated and automated approach to IHC staining.



NOVOCASTRA

RESULTS YOU CAN RELY ON

NOVOCASTRA PRIMARY ANTIBODIES



Spanning 14 pathology menus, Leica Biosystems offers laboratories a comprehensive range of clinically relevant antibodies for the most demanding workload.

Novocastra HD Antibodies

Each antibody in the Novocastra HD range has been independently evaluated¹ by an external QA scheme, in comparison with two market leading vendors. Each antibody within the HD portfolio has been optimized to deliver high quality staining, for results you can trust.

Novocastra BOND RTU

BOND Ready-to-Use antibodies are optimized to deliver high quality staining results on BOND systems. This format eliminates variability that can occur with manual antibody dilutions and also reduces preparation time. Pre-optimized reagents and automated protocols deliver consistent results you can depend on.

Novocastra Liquid Concentrates

The Novocastra liquid concentrated antibody range is an extensive collection of primary antibodies for IHC testing. Concentrated antibodies afford workflow flexibility, enabling users to optimize their protocols according to their pre-analytical conditions².

¹ Independent analysis commissioned by Leica Biosystems and conducted by NordiQC according to the manufacturers' instructions for use and on the corresponding staining platform.
² For recommended protocols see instructions for use. Any deviation from recommended conditions must be validated by the user.

Leica Biosystems is a global leader in workflow solutions and automation. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 9 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Visit LeicaBiosystems.com for more information.

Leica Biosystems is an international company with a strong network of worldwide customer services. For detailed contact information on your nearest sales office or distributor please visit our website:

LeicaBiosystems.com